Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data

Hepatology

Volumn 63, Issue 2, 2016, Pages 437-444

  Wilder, Julius M ^a   Jeffers, Lennox J ^b   Ravendhran, Natarajan ^c   Shiffman, Mitchell L ^d   Poulos, John ^e   Sulkowski, Mark S ^f   Gitlin, Norman ^g   Workowski, Kimberly ^h   Zhu, Yanni ⁱ   Yang, Jenny C ⁱ   Pang, Phillip S ⁱ   Mchutchison, John G ⁱ   Muir, Andrew J ^a   Howell, Charles ^j   Kowdley, Kris ^k   Afdhal, Nezam ^l   Reddy, K Rajender ^m  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Digestive Disease Associates   (United States)

^d Bon Secours Health System   (United States)

^e Fayetteville   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Atlanta Gastroenterology Associates   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ GILEAD SCIENCES   (United States)

^j HOWARD UNIVERSITY   (United States)

^k SWEDISH MEDICAL CENTER   (United States)

^l BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLACK PERSON; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT RESPONSE; ADOLESCENT; AFRICAN AMERICAN; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; HEPATITIS C, CHRONIC; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BENZIMIDAZOLES; FEMALE; FLUORENES; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; YOUNG ADULT;

EID: 84956845006     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28334     Document Type: Article

References (15)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. The Lancet Infect Dis 2005;5:558-567.
2. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl. 1):74-81.
3. Centers for Disease Control and Prevention. Hepatitis C information for health professionals Atlanta 2008. http://www.cdc.gov/hepatitis/hcv/. Accessed on July 10, 2015.
4. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714.
5. National Institutes of Health. NIH consensus statement on management of hepatitis C: 2002. NIH consensus and state-of-the-science statements. Bethesda, MD: National Institutes of Health; July 2002.
6. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
7. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000;119:1317-1323.
8. Muir AJ, Bornstein JD, Killenberg PG, Group ACHT. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-2271.
9. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-477.
10. Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012;57:24-31.
11. Harvoni (ledipasvir-sofosbuvir) tablets: U.S. prescribing information. Foster City, CA: Gilead Sciences, March 2015. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed on August 6, 2015.
12. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.
13. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
14. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-1888.
15. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:705-713.